Eculizumab proved a strong anti-inflammatory effect in neuromyelitis optica spectrum disorders (NMOSD), rare autoimmune diseases affecting the central nervous system in which aquaporin 4-immunoglobulin G (AQP4-IgG) is the main pathogenic antibody. Pregnancy in NMOSD patients is considered at high-risk for neurological and gynecological outcomes, requiring a careful consideration about treatment maintenance. In this case report, we describe a successful pregnancy, resulting in the birth of a healthy child, in a young woman with AQP4-IgG-seropositive NMOSD who was maintained on eculizumab during all pregnancy.
JariusSAktasOAyzenbergI, et al. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD)—Revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol2023; 270(7): 3341–3368.
2.
PaulFMarignierRPalaceJ, et al. International delphi consensus on the management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. Neurol Neuroimmunol Neuroinflamm2023; 10(4): e200124.
3.
Mao-DraayerYThielSMillsEA, et al. Neuromyelitis optica spectrum disorders and pregnancy: Therapeutic considerations. Nat Rev Neurol2020; 16(3): 154–170.
4.
SiriratnamPHudaSButzkuevenH, et al. Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive review. Autoimmunity Reviews2024; 23: 103499.
5.
WangLSuMZhouZ, et al. Analysis of pregnancy-related attacks in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. JAMA Netw Open2022; 5(8): E2225438.
6.
FujimotoTMaedaY. Eculizumab use throughout pregnancy in two patients with aquaporin-4-positive neuromyelitis optica spectrum disorder. Clin Exp Neuroimmunol2024; 15: 126–129.
7.
VuTHarveyBSureshN, et al. Eculizumab during pregnancy in a patient with treatment-refractory myasthenia gravis: A case report. Case Rep Neurol2021; 13(1): 65–72.
8.
SarnoLTufanoAMaruottiGM, et al. Eculizumab in pregnancy: A narrative overview. J Nephrol2019; 32(1): 17–25.
9.
SociéGCaby-TosiMPMarantzJL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol2019; 185(2): 297–310.
10.
KellyRArnoldLRichardsS, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol2010; 149(3): 446–450.
11.
HallstensenRFBergsethGFossS, et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology2015; 220(4): 452–459.
12.
MiyasakaNMiuraOKawaguchiT, et al. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: A Japanese experience and updated review. Int J Hematol2016; 103(6): 703–712.
